ArticleWorld journal of microbiology & biotechnology2025
Targeted inhibition of E. coli adhesion using antisense oligonucleotides: an approach to combat bacteria via CsrB targeting.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm is the most prevalent form of bacterial existence in natural environments and is associated with serious health conditions such as diarrhea and kidney failure. The carbon storage regulator A (CsrA) protein, along with its small regulatory RNAs CsrB and CsrC, plays a pivotal role in key cellular processes, including biofilm formation, motility, carbon metabolism, iron homeostasis, and stress response. In this study, a novel antisense oligonucleotide (ASO) was specifically designed to target and silence the csrB gene in Escherichia coli. The ASO was delivered using polyethyleneimine (PEI), and its efficacy was evaluated through gene expression analysis, colony-forming unit (CFU) assays, and crystal violet staining. Quantitative real-time PCR revealed a significant reduction in csrB and csrA expression in the treated O42 strain (p = 0.004 and p = 0.013, respectively), as well as a notable decrease in csrB expression in the O157 strain (p = 0.041). Furthermore, biofilm formation and bacterial adhesion were significantly reduced in the treated O42 strain (p = 0.046 and p = 0.028, respectively). These findings suggest that antisense oligonucleotides targeting small regulatory RNAs such as csrB may offer a promising therapeutic strategy for controlling biofilm-associated infections by disrupting key regulatory pathways in bacterial adhesion and biofilm development.
Indexed as
Identifiers
40325232What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.